Ozempic doesn't just reduce weight. Research shows GLP-1s also changes how much people spend on food, and the types of food ...

Hims & Hers Health (NYSE: HIMS) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. Is Hims & Hers ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

NerdWallet, Inc. does not offer advisory or brokerage services, nor does it recommend or advise investors to buy or sell particular stocks, securities or other investments.

Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and diabetes drugs exploding in popularity, even more expensive for Americans.

Growth stocks are equity shares likely to outperform their peers and the broader market. Here's a list of stocks that contain investment potential to beef up your portfolio.

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...